XPO1 inhibitors, Selinexor and Eltanexor showed increased efficacy in SF3B1-mutant (SF3B1 K700E and K666N) MDS patients in phase I/II clinical trial [146]. The gene discussed is SF3B1; the disease is myelodysplastic syndrome.